These findings demonstrate the contribution of CD147‐K148me2 to NSCLC immunosuppression and indicate that this modification is a potential target for NSCLC treatment from the perspective of eradicating tumor immunosuppression, which is expected to increase the effect of cancer immunotherapy for patients with NSCLC. This evidence concerns the gene BSG and cancer.